Alphatec Holdings, Inc. $ATEC Shares Bought by Parkman Healthcare Partners LLC

Key Points

• Parkman Healthcare Partners LLC increased its stake in Alphatec Holdings, Inc. by 95.4%, acquiring an additional 217,772 shares, resulting in a total of 446,106 shares valued at approximately $4.52 million.
• Alphatec recently reported quarterly earnings with an EPS of $0.02, beating estimates and showing a 27.5% increase in revenue year-over-year.
• Several hedge funds, including Comerica Bank and GAMMA Investing LLC, have significantly increased their positions in Alphatec, highlighting strong institutional interest as 66.35% of the stock is owned by institutional investors.

Parkman Healthcare Partners LLC lifted its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 95.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 446,106 shares of the medical technology company's stock after acquiring an additional 217,772 shares during the period. Parkman Healthcare Partners LLC owned 0.31% of Alphatec worth $4,524,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of ATEC. Comerica Bank lifted its holdings in shares of Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock worth $29,000 after acquiring an additional 1,248 shares during the period. Larson Financial Group LLC purchased a new position in Alphatec during the first quarter worth approximately $54,000. Lazard Asset Management LLC purchased a new position in Alphatec during the fourth quarter worth approximately $76,000. State of Wyoming purchased a new position in Alphatec during the fourth quarter worth approximately $86,000. Finally, Wexford Capital LP purchased a new position in Alphatec during the fourth quarter worth approximately $95,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Alphatec Stock Down 3.3%

ATEC traded down $0.54 during trading hours on Tuesday, reaching $15.80. 2,583,370 shares of the stock traded hands, compared to its average volume of 1,962,573. The firm's fifty day simple moving average is $13.58 and its two-hundred day simple moving average is $11.99. The company has a market cap of $2.34 billion, a price-to-earnings ratio of -13.98 and a beta of 1.02. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $16.70. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.08. The company had revenue of $185.54 million during the quarter, compared to the consensus estimate of $178.85 million. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. The company's revenue was up 27.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.29) EPS. Alphatec has set its FY 2025 guidance at EPS. As a group, analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Alphatec

In other Alphatec news, CEO Patrick Miles sold 300,000 shares of the business's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $15.73, for a total transaction of $4,719,000.00. Following the completion of the sale, the chief executive officer owned 5,564,078 shares in the company, valued at $87,522,946.94. The trade was a 5.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Scott Lish sold 6,323 shares of the business's stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $16.01, for a total transaction of $101,231.23. Following the sale, the chief operating officer owned 658,707 shares of the company's stock, valued at approximately $10,545,899.07. The trade was a 0.95% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 510,247 shares of company stock worth $7,627,527 in the last ninety days. 22.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ATEC. Barclays reaffirmed an "overweight" rating and set a $22.00 price target (up previously from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Canaccord Genuity Group reissued a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research report on Friday, August 1st. Wall Street Zen raised shares of Alphatec from a "hold" rating to a "buy" rating in a research report on Sunday. Finally, Lake Street Capital raised shares of Alphatec to a "buy" rating and set a $18.00 price objective for the company in a research report on Monday, June 16th. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $18.50.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.